What is Omnicell?
Medication-management automation and pharmacy software company with $1.185B 2025 revenue; 2026 guidance $1.215B-$1.255B scale.
- Category
- Medication-management automation and pharmacy software
- Headquarters
- Fort Worth, TX
- Founded
- 1992
- Employees
- 3,700+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: OMCL
What is Omnicell?
Omnicell is a Medication-management automation and pharmacy software company headquartered in Fort Worth, TX. As of June 2026, its clearest scale signal is $1.185B 2025 revenue; 2026 guidance $1.215B-$1.255B.
Omnicell operates a medication-management automation platform combining pharmacy robotics, cabinets, consumables, SaaS, and expert services. Its core customer set includes hospitals, health systems, pharmacies, medication-management teams, supply-chain leaders, and outpatient sites, and its public product surface includes Automated dispensing cabinets, Central pharmacy automation, IV compounding automation, Specialty pharmacy services, EnlivenHealth. The current scale signal is $1.185B 2025 revenue; 2026 guidance $1.215B-$1.255B, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Omnicell offer?
Omnicell offers Automated dispensing cabinets, Central pharmacy automation, IV compounding automation, Specialty pharmacy services and related healthcare workflows.
- Automated dispensing cabinets· Core product
- Central pharmacy automation· Core product
- IV compounding automation· Core product
- Specialty pharmacy services· Workflow
- EnlivenHealth· Workflow
- SaaS and Expert Services· Workflow
- Consumables· Platform
- Autonomous Pharmacy vision· Platform
How does Omnicell make money?
Omnicell earns product revenue from automation systems and recurring service revenue from technical services, SaaS, expert services, consumables, and support.
Omnicell earns product revenue from automation systems and recurring service revenue from technical services, SaaS, expert services, consumables, and support. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Large health-system deals are quoted by device footprint, cabinets, robots, software modules, implementation, consumables, support term, and managed-service scope rather than public list prices. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Omnicell?
Omnicell is led by Randall Lipps, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Randall LippsFounder, Chairman, President and Chief Executive OfficerFounder and CEOLeads the Autonomous Pharmacy strategy.
- Peter KuipersChief Financial OfficerCFOOwns finance, guidance, and capital allocation.
- Nnamdi NjokuChief Operating OfficerCOOLeads operations and customer execution.
- Scott SeidelmannChief Commercial OfficerCommercial leaderLeads commercial strategy and health-system growth.
How do you contact Omnicell's leadership?
Omnicell publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investor.relations@omnicell.com (official published/company IR contact); personal executive format not verified- Randall LippsFounder, Chairman, President and Chief Executive Officerinvestor.relations@omnicell.com
How much funding has Omnicell raised?
Omnicell is a public company (Nasdaq: OMCL), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
1992: Founded - Omnicell is founded to automate medication management in healthcare settings. 2001: IPO - Omnicell becomes a public company. 2015: Aesynt acquisition - Omnicell expands central pharmacy automation. 2021: FDS acquisition - Omnicell expands pharmacy services and EnlivenHealth capabilities. 2026: 2026 guidance - Management guides to $1.215B-$1.255B of 2026 revenue.
As of June 2026, Omnicell's practical funding capacity is best read through Nasdaq: OMCL, $1.185B 2025 revenue; 2026 guidance $1.215B-$1.255B, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Omnicell access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Omnicell get here?
Omnicell grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 1992Company foundedOmnicell begins with medication dispensing automation.
- 2001Nasdaq listingThe company becomes publicly traded.
- 2015Central pharmacy automationAesynt strengthens automation depth.
- 2020Autonomous PharmacyOmnicell frames automation, intelligence, and services around autonomous pharmacy.
- 2025Revenue growthThe company reports $1.185B in annual revenue.
- 2026ARR guidanceOmnicell guides to $680M-$700M of annual recurring revenue.
Who are Omnicell's competitors?
Omnicell competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- BDLarge medication-management, dispensing, and infusion technology competitor.
- Swisslog HealthcareHospital pharmacy automation and transport systems competitor.
- Capsa HealthcareMedication cart and point-of-care workflow competitor.
- ScriptProPharmacy automation systems competitor.
- McKessonPharmaceutical distribution and pharmacy-technology competitor.
- ARxIUMPharmacy automation, pouch packaging, and workflow competitor.
Omnicell — frequently asked questions
